ArticleStem cell reviews and reports2026
ANXA3 activates HIF-1α/VEGF Signaling Via the PI3K/AKT/mTOR Pathway to Promote Osteosarcoma Stem Cell-Like Phenotype.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAberrant activation of HIF‑1α contributes to the maintenance of CSC phenotypes in various malignancies. Our previous work revealed that ANXA3 is up‑regulated in OS cells. Here, we further investigated how ANXA3 regulates CSC‑like properties of OS cells through the HIF‑1α/VEGF signaling pathway.
methodsLentiviral vectors were used to modulate ANXA3 expression in OS cell lines. The expression of stemness‑associated genes was examined by qPCR and Western blotting, and sphere‑formation assays were performed to evaluate CSC self‑renewal capacity. Migration, invasion, and clonogenic survival under cisplatin treatment were assessed using Transwell and colony‑formation assays. An orthotopic intratibial implantation model in NOD-SCID mice was established to evaluate the effects of ANXA3 on tumor growth, metastasis, and CSC‑related features. Potential signaling mechanisms were analyzed by Western blotting and ELISA, and pathway‑specific inhibitors were applied to dissect the PI3K/Akt/mTOR-HIF‑1α/VEGF cascade.
resultsANXA3 expression was markedly elevated in osteosarcoma spheres compared with parental cells. ANXA3 knockdown down‑regulated stemness‑related genes, impaired sphere formation, and increased cisplatin sensitivity, whereas ANXA3 overexpression produced opposite effects. In vivo, ANXA3 silencing significantly suppressed tumor growth and pulmonary metastasis. Mechanistically, ANXA3 activated the PI3K/Akt/mTOR pathway, thereby enhancing HIF‑1α/VEGF expression. Knockdown of PI3K or HIF‑1α abrogated ANXA3‑induced stemness and chemoresistance, confirming the signaling axis mediates ANXA3‑driven oncogenic effects.
conclusionANXA3 plays a critical role in maintaining CSC‑like traits in osteosarcoma by up‑regulating the HIF‑1α/VEGF pathway in a PI3K/Akt/mTOR‑dependent manner. Targeting ANXA3 or its downstream signaling components may represent a promising therapeutic strategy for reversing CSC phenotypes and overcoming chemoresistance in osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.